Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

452.25 -2.71 (-0.60%)

Streaming Delayed Price Updated: 12:06 PM EST, Dec 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

69 70 Next >

4 First-in-Their-Class Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

November 11, 2023

A 15% decline in the Nasdaq Composite is a red-carpet opportunity for investors to snag high-quality growth stocks at a discount.

Via The Motley Fool

Topics Stocks

Amphastar Pharmaceuticals Stock Earns Composite Rating Upgrade ↗

November 10, 2023

Amphastar Pharmaceuticals stock saw its IBD SmartSelect Composite Rating rise to 98 Friday, up from 93 the day before.

Via Investor's Business Daily

Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review ↗

November 10, 2023

The major indexes ended long win streaks. Datadog led earnings winners.

Via Investor's Business Daily

What 10 Analyst Ratings Have To Say About Vertex Pharmaceuticals ↗

November 07, 2023

Via Benzinga

Earnings Scheduled For November 6, 2023 ↗

November 06, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.

Via Benzinga

Exploring NASDAQ:VRTX's quality characteristics. ↗

October 30, 2023

Reasonable Growth, Debt Levels, and a High ROIC Make VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) Appealing to Quality Investors.

Via Chartmill

3 Biotech Stocks That Are Betting on the Future of Gene Editing ↗

November 09, 2023

These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now.

Via InvestorPlace

This Program for a Common Problem May Be Vertex Pharmaceuticals' Ticket to a New Wave of Billion-Dollar Revenues ↗

November 09, 2023

Vertex shares look cheap today considering all the company has to offer.

Via The Motley Fool

Why you can make Vertex Pharmaceuticals a buy on any pullback

November 08, 2023

Vertex stock is off its all-time highs after a slight miss on revenue, but the company's robust pipeline gives investors a reason to watch VRTX stock closely

Via MarketBeat

4 Reasons to Worry About Vertex Pharmaceuticals -- Debunked ↗

November 08, 2023

No biotech stock is worry-free. But investors shouldn't fret about these four issues for Vertex.

Via The Motley Fool

Vertex Slouches After Tech Leader Reports Mixed Results; But Late-Stage Pipeline In Focus ↗

November 07, 2023

The company expects $9.85 billion in full-year sales of its cystic fibrosis treatments.

Via Investor's Business Daily

These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q3 Results ↗

November 07, 2023

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported upbeat earnings for its third quarter, while sales missed estimates.

Via Benzinga

Topics Earnings

S&P 500, Nasdaq Set To Break 6-Day Rally Today? Traders Await Fed Cues, Analyst Says Seasonal Rally Has Started With Gusto ↗

November 07, 2023

Sentiment appears to have dipped after a six-session winning streak. Stock futures indicate a modestly lower opening on Tuesday as small and mid-cap earnings reports gain momentum.

Via Benzinga

Topics Economy Stocks

Vertex Pharmaceuticals (VRTX) Q3 2023 Earnings Call Transcript ↗

November 07, 2023

VRTX earnings call for the period ending September 30, 2023.

Via The Motley Fool

Topics Earnings

Vertex Reports Third Quarter 2023 Financial Results

November 06, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners ↗

November 06, 2023

Roku vaulted 50% to become Ark Innovation's top holding.

Via Investor's Business Daily

US Stocks Set To Extend 5-Day Winning Streak Today? Traders Anxiously Watch Fed Speech, Climbing Bond Yields ↗

November 06, 2023

The market looks set to extend last week’s gains, with the stock futures holding up early Monday ahead of a slew of earnings reports mostly from the small and mid-cap space.

Via Benzinga

Topics Economy

Fed Holds Rates Steady, Powell's Cautious Stance Soothes Investors, Labor Market Softens: The Week In The Markets ↗

November 03, 2023

Markets bounced back decisively this week, shrugging off prior volatile months marked by heightened geopolitical tensions. The resurgence of risk sentiment ignited a relief rally in both equities and...

Via Benzinga

Topics Bonds Economy

Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review ↗

November 03, 2023

Bulls are back in control as the major indexes confirmed the uptrend this week.

Via Investor's Business Daily

Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA ↗

November 03, 2023

The meeting went almost as well as could be expected.

Via The Motley Fool

Vertex to Present New Data on Exagamglogene Autotemcel (exa-cel) at the American Society of Hematology (ASH) Annual Meeting and Exposition

November 02, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis Conference

November 02, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

One Month Ahead of its Most Crucial Moment Ever, Should You Buy CRISPR Therapeutics? ↗

November 02, 2023

This stock could be a long-term winner, thanks to its game-changing technology.

Via The Motley Fool

Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today ↗

November 01, 2023

Via Benzinga

Crispr Therapeutics Rallies On Bullish Views Of First-Ever Gene-Editing Drug ↗

November 01, 2023

The agency could soon approve a potential cure for sickle cell disease .

Via Investor's Business Daily

Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90 ↗

October 31, 2023

Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient ↗

October 30, 2023

This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term.

Via The Motley Fool

Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade ↗

October 28, 2023

4x returns in just a decade is quite an attainable result for these companies.

Via The Motley Fool

CRSP Stock: FDA Considers Additional Review of CRISPR Therapeutics Gene Therapy ↗

October 27, 2023

Although CRISPR Therapeutics may have a breakthrough drug on its hands, regulatory concerns hang over CRSP stock.

Via InvestorPlace

Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher ↗

October 27, 2023

A Relative Strength Rating upgrade for Rocket Pharmaceuticals shows improving technical performance. Will it continue?

Via Investor's Business Daily

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

69 70 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.